MX393982B - Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2). - Google Patents

Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2).

Info

Publication number
MX393982B
MX393982B MX2020000349A MX2020000349A MX393982B MX 393982 B MX393982 B MX 393982B MX 2020000349 A MX2020000349 A MX 2020000349A MX 2020000349 A MX2020000349 A MX 2020000349A MX 393982 B MX393982 B MX 393982B
Authority
MX
Mexico
Prior art keywords
hdac1
histone deacetylase
diseases
selective inhibitors
amide derivatives
Prior art date
Application number
MX2020000349A
Other languages
English (en)
Spanish (es)
Other versions
MX2020000349A (es
Inventor
Gómez Juan Camacho
Palomino Laria Julio Castro
Iglesias Rodolfo Rodríguez
Original Assignee
Medibiofarma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medibiofarma S L filed Critical Medibiofarma S L
Publication of MX2020000349A publication Critical patent/MX2020000349A/es
Publication of MX393982B publication Critical patent/MX393982B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2020000349A 2017-07-10 2018-07-09 Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2). MX393982B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382447 2017-07-10
PCT/ES2018/070491 WO2019012172A1 (es) 2017-07-10 2018-07-09 Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2)

Publications (2)

Publication Number Publication Date
MX2020000349A MX2020000349A (es) 2020-08-17
MX393982B true MX393982B (es) 2025-03-24

Family

ID=59315557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000349A MX393982B (es) 2017-07-10 2018-07-09 Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2).

Country Status (21)

Country Link
US (1) US11241428B2 (enExample)
EP (1) EP3653620B9 (enExample)
JP (1) JP7026787B2 (enExample)
KR (1) KR102574135B1 (enExample)
CN (1) CN111051300B (enExample)
AU (1) AU2018300123B2 (enExample)
CY (1) CY1125343T1 (enExample)
DK (1) DK3653620T3 (enExample)
EA (1) EA039144B1 (enExample)
ES (1) ES2911040T3 (enExample)
HR (1) HRP20220472T1 (enExample)
HU (1) HUE058353T2 (enExample)
LT (1) LT3653620T (enExample)
MX (1) MX393982B (enExample)
PL (1) PL3653620T3 (enExample)
PT (1) PT3653620T (enExample)
RS (1) RS63156B1 (enExample)
SI (1) SI3653620T1 (enExample)
SM (1) SMT202200165T1 (enExample)
WO (1) WO2019012172A1 (enExample)
ZA (1) ZA202000727B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
US20230119479A1 (en) * 2019-12-10 2023-04-20 Shionogi & Co., Ltd. A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group
CN114380751B (zh) * 2020-03-30 2025-03-07 上海辉启生物医药科技有限公司 二氢化茚胺类衍生物、其制备方法和用途
CA3240229A1 (en) 2021-12-03 2023-06-08 Tango Therapeutics, Inc. Novel hdac inhibitors and therapeutic use thereof
CN114524799B (zh) * 2022-03-11 2023-05-26 沈阳药科大学 一种hdac抑制剂及其制备方法和用途
EP4306106A1 (en) * 2022-07-14 2024-01-17 Universidade de Aveiro Nitro-containing compounds, compositions and uses thereof
CN115463215A (zh) * 2022-07-26 2022-12-13 苏州大学 Hdac9及其抑制剂的新用途
WO2024030659A1 (en) 2022-08-05 2024-02-08 Tango Therapeutics, Inc. An hdac inhibitor for treating cancer with a modified stk11 activity or expression
CN115304513A (zh) * 2022-08-25 2022-11-08 湖北科技学院 具有抗炎活性的查尔酮类衍生物及其合成方法和应用
CN115368277B (zh) * 2022-09-15 2024-03-29 华侨大学 一种含异羟肟酸结构的联苯类化合物及其应用
CN116199636A (zh) * 2023-02-21 2023-06-02 杭州医学院 靶向肿瘤免疫激酶的2,4-二取代嘧啶衍生物、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514859A (ja) * 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド 置換ニコチンアミド化合物
WO2007127137A2 (en) * 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
CA2763786C (en) * 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
US20160137630A1 (en) * 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
BR112017028139A2 (pt) * 2015-07-02 2018-08-28 Biomarin Pharmaceutical Inc. inibidores de histona desacetilase
US9603950B1 (en) 2015-10-25 2017-03-28 Institute Of Nuclear Energy Research Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof

Also Published As

Publication number Publication date
SI3653620T1 (sl) 2022-05-31
US11241428B2 (en) 2022-02-08
SMT202200165T1 (it) 2022-05-12
US20200138808A1 (en) 2020-05-07
MX2020000349A (es) 2020-08-17
ZA202000727B (en) 2022-07-27
KR102574135B1 (ko) 2023-09-01
WO2019012172A1 (es) 2019-01-17
CN111051300A (zh) 2020-04-21
CA3069273A1 (en) 2019-01-17
EA202090259A1 (ru) 2020-05-25
CY1125343T1 (el) 2024-12-13
AU2018300123A1 (en) 2020-02-13
EP3653620A1 (en) 2020-05-20
AU2018300123B2 (en) 2022-03-17
EP3653620B9 (en) 2022-03-23
JP2020527173A (ja) 2020-09-03
DK3653620T3 (da) 2022-03-28
EA039144B1 (ru) 2021-12-09
EP3653620B1 (en) 2022-02-02
PT3653620T (pt) 2022-04-22
JP7026787B2 (ja) 2022-02-28
RS63156B1 (sr) 2022-05-31
HUE058353T2 (hu) 2022-07-28
PL3653620T3 (pl) 2022-06-20
CN111051300B (zh) 2022-12-23
KR20200038473A (ko) 2020-04-13
LT3653620T (lt) 2022-05-10
BR112020000564A2 (pt) 2020-07-21
HRP20220472T1 (hr) 2022-05-27
ES2911040T3 (es) 2022-05-17

Similar Documents

Publication Publication Date Title
EA202090259A1 (ru) Новые гетероариламидные производные как селективные ингибиторы гистондеацетилаз 1 и/или 2 (hdac1-2)
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PH12015502425A1 (en) Novel compounds for selective histone deacetylase inhibitors, and pharmeceutical composition comprising the same
MX2020007265A (es) Derivados de rapamicina.
TW201612158A (en) Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof
EA201890618A1 (ru) Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
MX2020003488A (es) Acidos 3-alquil-4-amido-biciclico [4,5,0] hidroxamicos como inhibidores de histona desacetilasas (hdac).
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
MX376054B (es) Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo.
PH12017501160A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
PH12017501823B1 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
EA201992306A1 (ru) Ингибиторы ip6k
EA201790658A1 (ru) Производные диарилмочевины в качестве ингибиторов киназы p38
WO2016004404A3 (en) Gls1 inhibitors for treating disease
MX376283B (es) Compuestos de imidazopiridazina.
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.